Introduction
============

Preterm neonates show cortical ([@B01],[@B02]), biochemical ([@B03]), physiological ([@B04],[@B05]), and behavioral ([@B06],[@B07]) responses to painful procedures. Nonpharmacological management has been recommended for pain relief, such as nonnutritive sucking ([@B08]), breastfeeding ([@B09],[@B10]), skin-to-skin contact ([@B11],[@B12]), and sweetened solutions, including glucose ([@B13]), fructose ([@B14]), and sucrose ([@B15]-[@B19]).

Sucrose solution is recommended as relevant pain relief management in neonates during acute painful procedures ([@B19],[@B20]) and is included in the pain guidelines of Neonatal Intensive Care Units (NICUs) ([@B21]-[@B23]). The efficacy of oral sucrose solution for pain relief in preterm neonates was established as a single dose 2 min prior to acute painful procedures, using 2 mL 25% sucrose ([@B24],[@B25]). Additionally, the effectiveness of sucrose solution for pain relief has been established by scheduled administration of repeated doses during the same painful procedure ([@B26],[@B27]) and on consecutive days ([@B16],[@B18],[@B28]-[@B30]).

However, only a few studies with inconclusive findings have analyzed the potentially adverse effects of scheduled administration of sucrose solution in repeated doses on the developmental and clinical status of preterm neonates ([@B16],[@B18],[@B28],[@B31]). In one study, high-risk preterm infants using high doses of sucrose (≥10 per day) for pain relief showed low neurobehavioral development scores at 36 and 40 weeks postconception ([@B28]). In another, preterm infants also using sucrose exhibited normal development at 28 days postnatal age in comparison with control group given sterile water ([@B18]). In addition, no adverse effects of sucrose on clinical outcomes (i.e., occurrence of residues in the stomach, vomiting, and abdominal distension) were detected in preterm infants during the first and second postnatal weeks ([@B18]). Other potentially adverse effects include the alteration of glucose homeostasis, specifically hyperglycemia, but this is more of a theoretical adverse effect than a well-documented one ([@B17]).

To date, this is the first study analyzing the association of repeated doses of sucrose for acute pain relief management with the feeding patterns and weight gain of preterm infants. The aim of the present study was to examine the potential short-term side effects of using sucrose for pain relief on feeding patterns and weight gain of preterm infants during hospitalization and immediately postdischarge.

Material and Methods
====================

Study design
------------

The present study was a case-control study, with analysis of between-group differences. The sample comprised 43 preterm (\<37 weeks gestational age) and very low birth weight (\<1500 g) neonates who were hospitalized in the NICU of Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (Brazil). The neonates who had major congenital anomalies, intraventricular hemorrhage (grade III/IV), and hypoglycemia or hyperglycemia, or who were on opioid or sedative medications and an umbilical catheter in the first and second weeks of life were excluded.

The sample was divided into two groups: a sucrose group (SG) and a control group (CG). The SG included 18 neonates, of which 17 participants corresponded to secondary data of a randomized controlled trial study previously published that examined the analgesic effects and short-term adverse effects of repeated doses of sucrose over a 3-day period ([@B18]). The SG neonates received 0.5 mL/kg 25% oral sucrose 2 min before the following acute painful procedures: venipuncture, arterial puncture, heel lancing, intravenous cannulation, endotracheal tube introduction, endotracheal tube suctioning, gavage insertion for feeding, and the removal of electrode leads and tape. These procedures were selected based on the study of Johnston et al. ([@B28]), and the neonates received an average of six doses of sucrose per day ([@B18]).

The CG was composed of 25 neonates, who were hospitalized in the NICU at the same time as the SG, but they were immediately transferred to the Intermediary Special Care Nursery depending on the evolution of their clinical status. The CG did not receive sucrose during acute painful procedures. At the time of data collection, the great majority of studies had tested single doses of sucrose for pain relief ([@B32]). Then, a randomized controlled trial was carried out to examine the efficacy and side effects of repeated doses of a sucrose schedule (3-day period) for acute pain relief ([@B18]). We then collected data from the CG, because the pain management guidelines using sucrose had not yet been implemented.

Ethics approval
---------------

The Clinical Research Ethics Board of Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brazil, approved the present study. Informed written consent was obtained from all parents of the patients in the study prior to participation. This study was done prior to the implementation of sucrose for acute pain relief management as a routine clinical guideline in the NICU.

Measurements and procedure
--------------------------

Medical chart reviews were performed using a protocol for data collection by trained researchers. Infant characteristics and their clinical evolution were obtained. The main variables for analyzing the side effects of sucrose were the following: *a*) parenteral feeding, duration of orogastric tube use, weight at 38 weeks postconception, weight at discharge, weight gain between birth and 38 weeks postconception, and weight gain between birth and discharge (during hospitalization); and *b*) feeding pattern using human milk (postdischarge).

Data analysis
-------------

The Statistical Package for the Social Sciences (version 19.0, USA) was used for data analysis. The Shapiro-Wilk test was used to verify the normal distribution of the data, and, according to the results, a nonparametric statistical approach was adopted. The between-group comparisons (SG *vs* CG) were analyzed using the Mann-Whitney test for continuous variables and the chi-square test for categorical variables. The statistical significance level for all tests in this study was set at P≤0.05.

Results
=======

Characteristics of preterm infants and neonatal health status
-------------------------------------------------------------

The characteristics and clinical status of the preterm infants are reported in [Table 1](#t01){ref-type="table"}. There were no statistically significant differences between groups with regard to the following variables: gender, gestational age, neonatal clinical risk index, five-minute Apgar score, necrotizing enterocolitis, and length of stay in the hospital. However, the SG presented significantly lower birth weight than the CG.

Feeding and weight gain outcomes during hospitalization and postdischarge
-------------------------------------------------------------------------

The feeding patterns and weight gain of preterm neonates during hospitalization and postdischarge are reported in [Table 2](#t02){ref-type="table"}. There were no statistically significant differences between the SG and CG with regard to administration of parenteral feeding, duration of orogastric tube use, average weight at 38 weeks postconception and at discharge, weight gain between birth and 38 weeks postconception, and weight gain between birth and discharge.

There were no statistically significant differences between groups in the postdischarge patterns for feeding with human milk. Sixty-seven percent of the SG infants and 74% of the CG infants were fed with human milk, either by exclusive breastfeeding or by formula supplementation.

Discussion
==========

The findings of the present study showed that the preterm infants who received sucrose for acute pain relief in the NICU did not present adverse side effects in terms of their feeding patterns and weight gain. The SG presented a clinical evolution similar to the CG with regard to the duration of orogastric tube use, administration of parenteral feeding, and weight gain. In addition, the majority of the infants in the SG left the hospital being fed human milk, either by exclusive breastfeeding or with formula supplementation.

The indirect measurement of feeding tolerance was the time at which the infants received parenteral nutrition. Parenteral feeding is the recommended choice for the initial nutritional management of high-risk preterm infants, which leads to elevated costs for the healthcare system ([@B33]). In the clinical guidelines of the NICU in the current study, the preterm infants received parenteral feeding during the period when they did not tolerate enteral feeding. The tolerance of preterm infants for human milk was the main factor in deciding whether to make the transition from parenteral to enteral feeding. The similar duration of parenteral feeding in the two groups suggests that there was a similar feeding pattern in the evolution of these infants. The use of sucrose for pain relief in preterm infants did not influence dietary progression during hospitalization in the NICU.

Another concern is whether the repeated doses of sucrose that are used for pain relief provoke conditioning responses in preterm infants through association between the pleasant sweet taste and aversive painful stimuli. Studies have demonstrated evidence of potential conditioning responses in preterm neonates during painful or stressful procedures ([@B34]-[@B36]). If these learning conditioning mechanisms were established, the high-risk preterm infants could exhibit avoidance of oral sweet solutions during feeding, such as human milk.

Our results also do not confirm this association between the use of sucrose and avoidance of sweet feeding, and the two groups of preterm infants exhibited similar feeding patterns. There was a wide range in the duration of orogastric tube use in the sample study, but there were no differences between the SG and CG. In general, the duration of orogastric tube use in the NICU is associated with maturity levels of the infants with regard to their capacities for breathing, feeding, and swallowing; the lower the gestational age of the infants, the lower the coordination of these capacities, and, consequently, the longer the duration of orogastric tube use during hospitalization ([@B37]). Human milk tastes sweet and contains 7% sucrose. If there was a conditioned association, the preterm infants who received sucrose for pain relief could present avoidance to being fed human milk. Our findings did not confirm this association between sweet solutions and aversive stimuli; the percentage of preterm SG infants who accepted human milk was similar to those in the CG.

A recent study that evaluated the effects of breastfeeding for reducing minor procedural pain during NICU hospitalization did not show efficacy for pain relief in preterm infants born at 30-36 weeks gestational age, compared with a control group given soothing procedures ([@B10]). In addition, when pairing breastfeeding with a single blood collection, there were no adverse effects detected on immediate breastfeeding behavior, within the 24 h after the painful procedure. Our findings add to this previous study, in the sense that we examined the feeding pattern outcomes, including the days on parenteral nutrition and orogastric feeding, besides breastfeeding. In addition, we analyzed the feeding pattern during the entire time the infants were hospitalized and postdischarge, in addition to the length of time in the NICU.

Although many factors are involved in the growth of preterm infants, undoubtedly nutrition is one of the most relevant. The fact that the groups presented similar growth is a strong indication that they ingested similar quantities of nutrients. The diet offered to all infants was the same. It was initiated with early parenteral nutrition on the first day, which was maintained for the shortest possible time, depending on the acceptance of human milk. Although the pace of growth was a little slower with human milk, its multiple advantages far outweigh this limitation ([@B38]).

The final concern is whether the administration of sucrose in association with painful procedures could stimulate the behavior of seeking sweet food for comfort and support in coping with other stressful experiences. If this association was established, this could provoke subsequent obesity and behavioral disorders in children that were born preterm. Unfortunately, the design of the present study could not address questions concerning long-term impact. However, our findings suggest that, during the short-term hospitalization period, the infants in the SG had weights similar to those in the CG.

In conclusion, oral sucrose (0.5 mL/kg of a 25% solution, 2 min prior to acute painful procedures) for pain relief in preterm neonates was effective and safe, exhibiting no short-term adverse effects in weight gain and feeding patterns, during hospitalization and postdischarge. However, the present study has some limitations. This was an exploratory study about the effects of sucrose on feeding pattern outcomes, using secondary data. The schedule of three consecutive days for sucrose administration could be insufficient to show significant differences between groups. The sample was small and the data could have been underreported in medical chart recordings.

In spite of these limitations, this is the first study to analyze the potential short-term side effects of sucrose for pain relief on the growth and feeding pattern outcomes of infants. The present study included a convenient sample of vulnerable neonates with several criteria for inclusion and exclusion in the study. These criteria were strong factors regarding methodological care; however, their use limited the sample size of infants. The current study was ecologically valid because the sample population was assessed in the natural setting of the NICU, allowing for the generalization of findings for similar samples and conditions.

Future studies are needed to analyze the growth and feeding patterns in a larger sample, and also to follow preterm infants who receive sucrose for pain relief during their entire time of long-term hospitalization.
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